Regeneron Pharmaceuticals

Researchers are testing the drug cemiplimab, given alone or with other anti-cancer drugs, in people with locally advanced basal cell carcinoma that cannot be treated with surgery or radiation. The trial compares how well the combinations work against cemiplimab by itself and trac…

This Phase 3 trial tests garetosmab, an antibody that blocks activin A, in 18 children and teens with fibrodysplasia ossificans progressiva (FOP), a rare disease where muscle and tissue turn into bone. The study will check safety, side effects, and whether the drug reduces new ab…

This trial tests three experimental antibodies—REGN9933, REGN7508, and REGN9533—in people with end-stage kidney disease who are on hemodialysis. The goal is to see if these antibodies can safely reduce blood clot risk during dialysis, potentially offering an alternative to standa…

This trial is testing an experimental drug called REGN17235 in people with two related blood conditions: clonal cytopenia of undetermined significance (CCUS) and low-risk myelodysplastic syndrome (MDS), both linked to a specific genetic change called an SF3B1 mutation. The main g…

This study tests two experimental drugs, REGN7508 and REGN9933, to see if they can prevent blood clots in people who have a peripherally inserted central catheter (PICC). People with PICCs are at higher risk for venous thromboembolism (VTE), which can be serious. The trial compar…

This study tests an experimental drug called REGN22530 in people with primary open angle glaucoma or ocular hypertension. The drug is designed to block a protein in the eye that causes fluid buildup and high pressure. Researchers are checking for side effects, how the drug moves …

This study tests an experimental drug called ALN-CIDEB in 150 adults with MASH, a serious liver disease involving fat buildup and scarring. The goal is to see if the drug can reduce liver fat, injury, and scarring compared to a placebo. Participants will receive either the drug o…

This study tests whether adding dupilumab to standard COPD treatment can prevent another flare-up or hospital stay within 90 days. About 754 adults who were recently hospitalized for a COPD exacerbation will receive either dupilumab or a placebo. The goal is to see if the drug re…

This study tests two immunotherapy drugs, fianlimab and cemiplimab, in children and young adults with recurrent high-grade glioma or ependymoma. The goal is to see if the combination is safe and can shrink tumors or slow their growth. Participants will receive the drugs before an…

This study aims to identify and describe people with allergic conjunctivitis (eye allergies) caused by cats or birch tree pollen, with or without accompanying allergic rhinitis (hay fever). Researchers will collect information and perform allergy tests to see who qualifies for fu…